CODUPHA CENTRAL PHARMACEUTICAL COMPANY JSC

No: 81 /CDP/2025

THE SOCIALIST REPUBLIC OF VIETNAM Independence - Freedom - Happiness

HCM City, January 22, 2025

INFORMATION DISCLOSURE

- Name of company: Codupha Central Pharmaceutical Company JSC
- Transaction name: CODUPHA
- Address of headoffice: 262L Le Van Sy Street, Ward 14, Distreet 03, Ho Chi Minh City.
- Phone: 02838 651909

Fax: 028 38650750

- Stock Code: CDP
- Person responsible for disclosure of information: Chi Thi Bich Hong Deputy Head of Finance and Accounting Department
- Address: 356/27 Pham Van Bach Street, Ward 15, Distreet Tân Bình, Ho Chi Minh City
- Type of information disclosed irregularly: 24h

Content of disclosed information:

- Separate and consolidated financial statements for Q4/2024
- Explanation profit after Corporate Income Tax changed by more than 10% on the financial statements of Q4/2024 compared to Q4/2023

This information has been published on the official website of Central Pharmaceutical Joint Stock Company Codupha at http://www.codupha.com.vn.

We commit that the information disclosed above is true and take full legal responsibility for the content of the disclosed information.

Recipients:

- State Securities Commission
- Stock Exchange
- Finance and Accounting Department
- Storage

PERSON RESPONSIBLE FOR DISCLOSURE OF INFORMATION

CODUPHA

CODUPHA

CODUPHA

CODUPHA

CN. Chu Thị Bích Hồng

CODUPHA CENTRAL PHARMACEUTICAL COMPANY JSC

No: 82 /2025/CDP

THE SOCIALIST REPUBLIC OF VIETNAM Independence - Freedom - Happiness

HCM City, January 22, 2025

TO: State Securities Commission State Securities Commission Hanoi Stock Exchange

Based on Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance on "Guidelines for Information Disclosure on the Securities Market".

Based on the consolidated financial statements of the fourth quarter of 2024 of Central Pharmaceutical Joint Stock Company Codupha, as disclosed.

Central Pharmaceutical Joint Stock Company Codupha provides the following explanation: Profit after Corporate Income Tax changed by more than 10% on the financial statements of Q4/2024 compared to Q4/2023. (According to Section a, Clause 4, Article 14, Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance)

A/ Separate and consolidated business results report for Q4/2024:

Đvt: VND

No.	Indicator	SEPARATE FINANCIAL STATEMENT				
		Q4.2024	Q4.2023	Amount Discrepancy	Percentage of Increase/ Decrease	
	1	2	3	4=(2-3)	5 =4/5	
	Profit after Corporate Income Tax	3.784.763.334	3.698.315.238	86.448.096	2,34%	

No.	Indicator	CONSOLIDATED FINANCIAL STATEMENT				
		Q4.2024	Q4.2023	Amount Discrepancy	Percentage of Increase/ Decrease	
	1	2	3	4=(2-3)	5 =4/5	
	Profit after Corporate Income Tax	2.904.218.153	1.685.282.416	1.218.935.737	72,33%	

CÔ! CÔ! DƯỢC PHÂM B/ Reasons: The consolidated financial statements have led to a discrepancy in the profit after corporate income tax in Q4/2024 compared to the same period last year for the Company due to:

- Sales service revenue in Q4/2024 was higher than the same period: Increased revenue from Hisamitsu goods, commission goods fees, etc.
- Cost of goods sold in Q4/2024 was higher than the same period, increased due to some high gross profit items.
- Administrative expenses in Q4/2024 decreased compared to the same period as the Company reduced provisions for overdue receivables.

The above is the explanation of Central Pharmaceutical Joint Stock Company Codupha regarding the changes in consolidated business results in Q4/2024 compared to Q4/2023.

Central Pharmaceutical Joint Stock Company Codupha hereby informs the State Securities Commission and the Hanoi Stock Exchange.

Sincerely,

CODUPHA CENTRAL PHARMACEUTICAL
COMPANY JSC

GENERAL DIRECTOR

CODUPHA AVIA

CÔNG TY CỔ PHẨN ĐƯỢC PHẨM TRUNG ƯƠNG

